PURPOSE: AGS-1C4D4 is a human monoclonal antibody against prostate stem cell antigen (PSCA), a cell-surface protein expressed by most prostate cancers. AGS-1C4D4 is produced in Chinese hamster ovary (CHO) cells and has an identical sequence to AGS-PSCA, an anti-PSCA antibody produced in mouse hybridoma cells that has completed Phase I testing. Preclinical studies demonstrated comparability of AGS-1C4D4 to AGS-PSCA with respect to pharmacokinetics (PK) and tumor inhibition. However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK. PATIENTS AND METHODS: Thirteen patients with metastatic castration-resistant prostate cancer were enrolled. AGS-1C4D4 was administered intravenously every 3 weeks for four planned doses at 6, 12, 24, or 48 mg/kg. Primary endpoints were safety and PK. Secondary endpoints were immunogenicity and clinical activity. Disease assessments were conducted every 12 weeks and included radiographic and PSA evaluations. Patients with stable disease could receive extended treatment beyond four infusions. RESULTS: Adverse events were primarily grade 1-2, without any grade 3-4 drug-related toxicities or infusion reactions. Anti-AGS-1C4D4 antibodies were not detected. Similar to AGS-PSCA, serum AGS-1C4D4 concentrations declined biphasically and elimination was characterized by slow clearance (CL) and a long terminal half-life (t (1/2)). Median CL for the four dose levels ranged from 0.10 to 0.14 ml/h kg, and t (1/2) ranged from 2.2 to 2.9 weeks. No PSA reductions ≥50% were observed. Six patients (46%) had radiographically stable disease, lasting a median of 24 weeks. CONCLUSION: AGS-1C4D4 was well-tolerated and demonstrated linear PK. Despite preclinical differences in antibody-dependent cellular cytotoxicity, AGS-1C4D4 and AGS-PSCA have similar safety and PK profiles. The recommended Phase II dose is 48 mg/kg.
PURPOSE:AGS-1C4D4 is a human monoclonal antibody against prostate stem cell antigen (PSCA), a cell-surface protein expressed by most prostate cancers. AGS-1C4D4 is produced in Chinese hamster ovary (CHO) cells and has an identical sequence to AGS-PSCA, an anti-PSCA antibody produced in mouse hybridoma cells that has completed Phase I testing. Preclinical studies demonstrated comparability of AGS-1C4D4 to AGS-PSCA with respect to pharmacokinetics (PK) and tumor inhibition. However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK. PATIENTS AND METHODS: Thirteen patients with metastatic castration-resistant prostate cancer were enrolled. AGS-1C4D4 was administered intravenously every 3 weeks for four planned doses at 6, 12, 24, or 48 mg/kg. Primary endpoints were safety and PK. Secondary endpoints were immunogenicity and clinical activity. Disease assessments were conducted every 12 weeks and included radiographic and PSA evaluations. Patients with stable disease could receive extended treatment beyond four infusions. RESULTS: Adverse events were primarily grade 1-2, without any grade 3-4 drug-related toxicities or infusion reactions. Anti-AGS-1C4D4 antibodies were not detected. Similar to AGS-PSCA, serum AGS-1C4D4 concentrations declined biphasically and elimination was characterized by slow clearance (CL) and a long terminal half-life (t (1/2)). Median CL for the four dose levels ranged from 0.10 to 0.14 ml/h kg, and t (1/2) ranged from 2.2 to 2.9 weeks. No PSA reductions ≥50% were observed. Six patients (46%) had radiographically stable disease, lasting a median of 24 weeks. CONCLUSION:AGS-1C4D4 was well-tolerated and demonstrated linear PK. Despite preclinical differences in antibody-dependent cellular cytotoxicity, AGS-1C4D4 and AGS-PSCA have similar safety and PK profiles. The recommended Phase II dose is 48 mg/kg.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: John S Lam; Joyce Yamashiro; I Peter Shintaku; Robert L Vessella; Robert B Jenkins; Steve Horvath; Jonathan W Said; Robert E Reiter Journal: Clin Cancer Res Date: 2005-04-01 Impact factor: 12.531
Authors: R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte Journal: Proc Natl Acad Sci U S A Date: 1998-02-17 Impact factor: 11.205
Authors: D C Saffran; A B Raitano; R S Hubert; O N Witte; R E Reiter; A Jakobovits Journal: Proc Natl Acad Sci U S A Date: 2001-02-13 Impact factor: 11.205
Authors: Z Gu; G Thomas; J Yamashiro; I P Shintaku; F Dorey; A Raitano; O N Witte; J W Said; M Loda; R E Reiter Journal: Oncogene Date: 2000-03-02 Impact factor: 9.867
Authors: P Argani; C Rosty; R E Reiter; R E Wilentz; S R Murugesan; S D Leach; B Ryu; H G Skinner; M Goggins; E M Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban Journal: Cancer Res Date: 2001-06-01 Impact factor: 12.701
Authors: Ken-Ryu Han; David B Seligson; Xueli Liu; Steve Horvath; Peter I Shintaku; George V Thomas; Jonathan W Said; Robert E Reiter Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Yi-Ping Fu; Indu Kohaar; Nathaniel Rothman; Julie Earl; Jonine D Figueroa; Yuanqing Ye; Núria Malats; Wei Tang; Luyang Liu; Montserrat Garcia-Closas; Brian Muchmore; Nilanjan Chatterjee; McAnthony Tarway; Manolis Kogevinas; Patricia Porter-Gill; Dalsu Baris; Adam Mumy; Demetrius Albanes; Mark P Purdue; Amy Hutchinson; Alfredo Carrato; Adonina Tardón; Consol Serra; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; W Ryan Diver; Susan M Gapstur; Michael J Thun; Jarmo Virtamo; Stephen J Chanock; Joseph F Fraumeni; Debra T Silverman; Xifeng Wu; Francisco X Real; Ludmila Prokunina-Olsson Journal: Proc Natl Acad Sci U S A Date: 2012-03-13 Impact factor: 11.205
Authors: Somala Mohammed; Sujita Sukumaran; Pradip Bajgain; Norihiro Watanabe; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; William E Fisher; Ann M Leen; Juan F Vera Journal: Mol Ther Date: 2017-01-04 Impact factor: 11.454
Authors: B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo Journal: Ann Oncol Date: 2013-02-28 Impact factor: 32.976
Authors: Indu Kohaar; Patricia Porter-Gill; Petra Lenz; Yi-Ping Fu; Adam Mumy; Wei Tang; Andrea B Apolo; Nathaniel Rothman; Dalsu Baris; Alan R Schned; Kris Ylaya; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Debra T Silverman; Stephen M Hewitt; Lee E Moore; Ludmila Prokunina-Olsson Journal: J Natl Cancer Inst Date: 2012-12-23 Impact factor: 13.506